Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent HPV Vaccine Efficacy in Chinese Females
NCT05584332Phase 3Terminated
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CERVAVAC in human papillomavirus infection, Cervical Cancer (CC), genital warts and 3 more (2 arms), sponsored by Shanghai Bovax Biotechnology Co., Ltd. Primary endpoint: Person-year incidence of HPV 16 and 18-related CIN 2+ at 30 months. Started Dec 2022; status: terminated.
02
Drugs
CERVAVAC
03
Conditions
human papillomavirus infectionCervical Cancer (CC)genital wartsvulvar intraepithelial neoplasia (VIN)vaginal intraepithelial neoplasia (VAIN)
Beyond the preview
Go deeper on NCT05584332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05584332.